<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Drugs><Drug><Id>13162</Id><DrugType><Type>Small molecule therapeutic</Type></DrugType><DrugTargetMaturity><TargetIndication><IndicationId>981</IndicationId><IndicationName>Hypogonadism</IndicationName><MinPatentApplicationDate>1998-05-29T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-00135</TargetId><TargetName>Androgen receptor</TargetName></TargetIndication><TargetIndication><IndicationId>1276</IndicationId><IndicationName>Female sexual dysfunction</IndicationName><MinPatentApplicationDate>2000-06-09T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-00135</TargetId><TargetName>Androgen receptor</TargetName></TargetIndication></DrugTargetMaturity><DevelopmentStatusCurrent><Row><Company id="26192">Endo Health Solutions Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2011-02-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1206939"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2012-03-19T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1424553"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2008-08-20T00:00:00Z</StatusDate><SourceLink type="PR" id="937041"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="811092"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="811092"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><SourceLink type="OTHER" id="1438015"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><SourceLink type="OTHER" id="1403074"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><SourceLink type="OTHER" id="1432127"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="XQ">Nordic countries</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-08-01T00:00:00Z</StatusDate><SourceLink type="PR" id="817965"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-08-15T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1458890"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><SourceLink type="OTHER" id="1365115"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2005-06-24T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1414450"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-06-11T00:00:00Z</StatusDate><SourceLink type="PR" id="803753"/></Row><Row><Company id="27664">Orexo AB</Company><Country id="XQ">Nordic countries</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-08-01T00:00:00Z</StatusDate><SourceLink type="PR" id="817965"/></Row><Row><Company id="1027766">PT Kalbe Farma Tbk</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2018-02-18T00:00:00Z</StatusDate><SourceLink type="OTHER" id="2166792"/></Row><Row><Company id="27477">Paladin Labs Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2011-01-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1161034"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="1125112"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="1125112"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="1125112"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="1125112"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XV">Pacific Rim</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="1125112"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="1125112"/></Row><Row><Company id="1033378">PDI Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2005-05-02T00:00:00Z</StatusDate><SourceLink type="PR" id="1206088"/></Row><Row><Company id="1033378">PDI Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2005-05-02T00:00:00Z</StatusDate><SourceLink type="PR" id="1206088"/></Row><Row><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><StatusDate>2006-03-08T00:00:00Z</StatusDate></Row><Row><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortorder="1">Outlicensed</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2006-11-29T00:00:00Z</StatusDate><SourceLink type="PR" id="747196"/></Row></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Row><Company id="26192">Endo Health Solutions Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-12-29T00:00:00Z</StatusDate><SourceLink type="PR" id="1158138"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2006-04-11T00:00:00Z</StatusDate><SourceLink type="PR" id="661277"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="GR">Greece</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-05-18T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1441310"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2006-08-04T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1403074"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2006-07-13T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1432126"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-01-17T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1365115"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2004-12-30T00:00:00Z</StatusDate><SourceLink type="PR" id="577835"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2010-12-29T00:00:00Z</StatusDate><SourceLink type="PR" id="1158138"/></Row><Row><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2002-06-03T00:00:00Z</StatusDate><SourceLink type="PR" id="453374"/></Row><Row><Company id="26192">Endo Health Solutions Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2009-08-26T00:00:00Z</StatusDate><SourceLink type="PR" id="1037054"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2005-11-08T00:00:00Z</StatusDate><SourceLink type="PR" id="633154"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2004-09-07T00:00:00Z</StatusDate><SourceLink type="PR" id="563134"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2002-06-04T00:00:00Z</StatusDate><SourceLink type="PR" id="453374"/></Row><Row><Company id="1033378">PDI Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2002-12-31T00:00:00Z</StatusDate><SourceLink type="PR" id="475304"/></Row><Row><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><StatusDate>2002-03-26T00:00:00Z</StatusDate><SourceLink type="PR" id="444857"/></Row><Row><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2003-07-07T00:00:00Z</StatusDate><SourceLink type="PR" id="496095"/></Row><Row><Company id="1010792">Kyowa Kirin</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2007-08-20T00:00:00Z</StatusDate><SourceLink type="PR" id="823726"/></Row><Row><Company id="1033378">PDI Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2003-07-07T00:00:00Z</StatusDate><SourceLink type="PR" id="496096"/></Row><Row><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>1999-02-11T00:00:00Z</StatusDate><SourceLink type="PR" id="314726"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2008-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="966840"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2008-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="966840"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2008-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="966840"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2008-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="966840"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XV">Pacific Rim</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2008-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="966840"/></Row><Row><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2008-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="966840"/></Row><Row><Company id="1033378">PDI Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2002-12-31T00:00:00Z</StatusDate><SourceLink type="PR" id="475304"/></Row><Row><Company id="1027766">PT Kalbe Farma Tbk</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="981">Hypogonadism</Indication><StatusDate>2005-03-09T00:00:00Z</StatusDate><SourceLink type="PR" id="588878"/></Row></DevelopmentStatusHistoric></Drug></Drugs>